FDA tells court mifepristone safety review will not be completed until March and will not add new restrictions before then

The Food and Drug Administration told a federal court it will not complete and publish its safety review of mifepristone until March, and it said the agency will not impose any new restrictions on the drug before then. The disclosure, made in a Wednesday court filing, came as litigation and public advocacy have pushed for faster regulatory action on the abortion medication.

According to the filing described by The Hill, FDA’s review schedule would delay any final agency safety determination and associated regulatory steps that could affect how mifepristone is prescribed and distributed. FDA’s stated timing means the next major regulatory milestone on the drug would occur after the agency completes its internal review work and publishes the results.

FDA also said it would not put additional restrictions in place before the March completion of the review. That position is designed to preserve the current regulatory posture for the time being, while the agency conducts the safety assessment and prepares whatever conclusions it will reach by publication.

The filing adds to pressure from abortion-rights and anti-abortion activists, who have criticized the pace and scope of federal review for mifepristone. The Hill reported that the new timeline is likely to further anger activists opposed to medication abortion, who have been calling for quicker changes.

The court filing does not, in the reporting summary, identify a specific case outcome or direct how the litigation will proceed once FDA publishes its review. Instead, it clarifies what the agency expects to do on its own timetable, including the absence of new restrictions prior to March.

The practical impact of the delay, based on FDA’s stated approach, is that any potential changes tied to the review would be deferred until after the agency completes its work and issues its findings. For patients, clinicians, and pharmacies, that means the interim period would continue under whatever existing FDA rules apply to mifepristone during the agency’s review window.

While federal courts often oversee regulatory disputes through injunctions or orders, this disclosure centers on FDA’s administrative schedule and its near-term decision not to expand restrictions before completing its safety analysis.

The next step, as outlined by the filing, is FDA’s publication of the mifepristone safety review in March. Depending on the outcome of the review and how courts address pending requests, the agency’s conclusions could become a key reference point for future arguments about the drug’s safety and permissible regulatory controls.